Plasma D‐dimer and interleukin‐6 are associated with treatment response and progression‐free survival in advanced NSCLC patients on anti‐PD‐1 therapy

BACKGROUND/AIMS: Response to therapy after using immune checkpoint inhibitors (ICIs) is unpredictable due to significant interindividual variation in efficacy among advanced non‐small cell lung cancer (NSCLC) patients. The current study centered on the identification of perivascular blood biomarkers...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chong, Yin, Huaru, Zhang, Yu, Chen, Huan, Xu, Jie, Ren, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469714/
https://www.ncbi.nlm.nih.gov/pubmed/37326149
http://dx.doi.org/10.1002/cam4.6222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469714/
https://www.ncbi.nlm.nih.gov/pubmed/37326149
http://dx.doi.org/10.1002/cam4.6222

Ejemplares similares